News Releases

Feb 07, 2022
Akouos Presents Nonclinical Data Demonstrating Potential Applicability of Precision Genetic Medicine Platform for a Broad Range of Inner Ear Conditions at the Association for Research in Otolaryngology 45th Annual Mid-Winter Meeting
- Data from two nonclinical studies evaluating protein expression and tolerability support future clinical development of AK-antiVEGF for the treatment of vestibular schwannoma - AAVAnc80 and a supporting cell selective promoter can drive widespread GJB2 expression in supporting cells, while
Additional Formats
Jan 31, 2022
Akouos to Participate in Upcoming February Virtual Investor Conferences
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that members of the management team will participate
Additional Formats
Displaying 11 - 13 of 13